Eli Lilly LLY 1.34% agreed to acquire Verve Therapeutics VERV -0.37% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...

Reports Q3 revenue $2.77B, consensus $2.41B. Eli Glickman, ZIM President & CEO, stated, “ZIM delivered strong Q3 results, as we again achieved record carried volumes contributing to our ...

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment, Lilly said on Tuesday ...

Eli Glickman, the CEO of ZIM Integrated (ZIM), is said to be considering a management-led buyout of the shipper, according to Street Insider, ci ...

ZIM Integrated (ZIM) surged 6.8% amid takeover speculation by CEO Eli Glickman. Stay updated as Q4 results are set to release this Wednesday.